Arrhythmias & electrophysiologyCohort study

Catheter ablation of atrial fibrillation in patients with cardiac amyloidosis and sarcoidosis: procedural findings and outcomes

EuropacePublished

  • Propensity-score matched cohort study
  • 1:4 matching

Authors' conclusion

Patients with infiltrative cardiomyopathies exhibit higher rates of non-PV triggers and left AFLs during first-time AF ablation. Those with cardiac amyloidosis experience higher arrhythmia recurrence rates compared with controls.

Study context

Population
Patients with cardiac amyloidosis or cardiac sarcoidosis undergoing first-time atrial fibrillation (AF) ablation
Participants
24 / 96 / 17 / 68
Exposure
AF ablation in cardiac amyloidosis or cardiac sarcoidosis vs matched controls
  • Cardiac amyloidosisn = 24
  • Amyloidosis controlsn = 96reference
  • Cardiac sarcoidosisn = 17
  • Sarcoidosis controlsn = 68reference
Outcome
Procedural findings: non-PV triggers and macro-reentrant atrial flutters

Main finding

As reported in the abstract

Non-PV triggers
Odds ratio (95% CI)
Cardiac amyloidosis vs Amyloidosis controls
4.5(1.4–14.2)
Cardiac sarcoidosis vs Sarcoidosis controls
2.7(0.6–12.6)

Observational data: associations, not effects.

Further findings

OutcomeCardiac amyloidosisAmyloidosis controlsCardiac sarcoidosisSarcoidosis controlsOR (95% CI)P value
Left atrial macro-reentrant flutters (amyloidosis)37.5%6.3%Not reported in the abstractNot reported in the abstract9.0 (2.8–29.0)

Recurrence (AF/AT/AFL ≥ 30 s after 90-day blanking) · 1 year — Cardiac sarcoidosis vs Sarcoidosis controls

P = 0.965

OutcomeEstimateP value
Recurrence (AF/AT/AFL ≥ 30 s after 90-day blanking) · 1 year — Cardiac amyloidosis vs Amyloidosis controlsP = 0.049

Original publication

Catheter ablation of atrial fibrillation in patients with cardiac amyloidosis and sarcoidosis: procedural findings and outcomes. Europace. Published 20 June 2025. doi:10.1093/europace/euaf100

Summarised from the published abstract; every number is checked against it